NCT06314490View on ClinicalTrials.gov

Personalized Antisense Oligonucleotide Therapy for Rare Pediatric Genetic Disease: SCN2A

PHASE1/PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

1

Participants

Timeline

Start Date

February 16, 2024

Primary Completion Date

February 16, 2026

Study Completion Date

February 16, 2026

Conditions
Genetic Disease
Interventions
DRUG

nL-SCN2A-002

Personalized antisense oligonucleotide

Trial Locations (1)

92123

Rady Children's Hospital, San Diego

All Listed Sponsors
collaborator

California Institute for Regenerative Medicine (CIRM)

OTHER

collaborator

n-Lorem Foundation

OTHER

lead

University of California, San Diego

OTHER

NCT06314490 - Personalized Antisense Oligonucleotide Therapy for Rare Pediatric Genetic Disease: SCN2A | Biotech Hunter | Biotech Hunter